Publications

484 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Migalastat (Galafold®) for the treatment of Fabry's disease

The National Health Care Institute carried out an assessment of whether, based on the criteria of the Medicines Reimbursement ...

Report | 25-04-2017
Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome

The National Health Care Institute carried out a reassessment of the medicinal product elosulfase alfa (Vimizim®). This report is ...

Report | 24-04-2017
Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

The National Health Care Institute carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line ...

Report | 24-04-2017
Cysteamine with delayed release (Procysbi®)

The National Health Care Institute Institute carried out an assessment of the medicine cysteamine with delayed release ...

Report | 23-03-2017
A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education

Summary of the second report of The Committee Innovation Health Care Professions & Education. This report is a summary of ...

Report | 23-03-2017
Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)

The National Health Care Institute carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came ...

Report | 15-12-2016
Palbociclib (Ibrance®) for the treatment of metastatic breast cancer

The National Health Care Institute carried out an assessment of the medicine palbociclib (Ibrance®), whereby they came to the ...

Report | 15-12-2016
Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy

The National Health Care Institute has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the ...

Report | 31-10-2016
Zinnige Zorg room for improvement report - Appropriate use of pharmaceutical products for patients with castration-refractory prostate cancer (CRPC)

Within the framework of the Zinnige Zorg Programme, Zorginstituut Nederland systematically assesses the Dutch minimal and ...

Report | 29-07-2016
Zinnige Zorg room for improvement report - Appropriate post-treatment surveillance of women treated for breast cancer

Within the framework of the Zinnige Zorg Programme, the National Health Care Institute systematically assesses the Dutch minimal ...

Report | 25-07-2016

Publications

484 publications

Migalastat (Galafold®) for the treatment of Fabry's disease

Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome

Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

Cysteamine with delayed release (Procysbi®)

A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education

Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)

Palbociclib (Ibrance®) for the treatment of metastatic breast cancer

Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy

Zinnige Zorg room for improvement report - Appropriate use of pharmaceutical products for patients with castration-refractory prostate cancer (CRPC)

Zinnige Zorg room for improvement report - Appropriate post-treatment surveillance of women treated for breast cancer

Go to